The FDA has approved the first treatment to increase pain-free light exposure in patients with the rare disorder, erythropoietic protoporphyria.
List view / Grid view
Filter the results
Rituxan (rituximab) is the first approved treatment for children with rare vasculitis diseases, in which a patient’s small blood vessels become inflamed.
The drug daratumumab has been approved for treatment of multiple myeloma, demonstrating increased efficacy when used in combination with other drugs.
The characterization of novel therapeutics involves many chemical processes.
Differential scanning calorimetry (DSC) has been one of the most widely used techniques to characterise the temperature stability of monoclonal antibodies (mAbs) and provide important information in formulation optimisation. However, despite its widespread use, not all the information contained in DSC data, especially denaturation kinetics, is routinely extracted. In this…
Get QC Results for Advanced Therapy Medicinal Products (ATMPs) Before Treatment.
British Columbia has said it will switch as many as 20,400 patients from three branded biologic drugs to cheap biosimilars.
Immunotherapy drug plus targeted agent provided better progression-free survival and shrank tumors in more patients than standard one-drug treatment...
Campaigners call for UK Government to intervene on pricing dispute over cystic fibrosis drug Orkambi...
A team of university researchers have collaborated together to develop a method to produce the radioisotope Tc-99m in the US to prevent having to import it...
A complete workflow to quantify intact therapeutic proteins in plasma matrix has been developed, covering three critical components in preclinical sample analysis: target protein enrichment/purification, LC/MS data acquisition and quantitative data analysis.
Whitepaper: Characterising antibody-drug conjugates using micro pillar array columns combined with mass spectrometry (μPAC™-MS)
The use of micro pillar array columns (μPAC™) for characterising antibody-drug conjugates is presented. Kadcyla® (ado-trastuzumab emtansine) and, for comparison, Herceptin® (trastuzumab) tryptic digests were analysed on a 200 cm μPAC™ C18 column and peaks eluting were detected by ultraviolet (UV) spectroscopy and high-resolution mass spectrometry (MS).
A combination of chemotherapy and immunotherapy could soon be used in NHS hospitals for triple-negative breast cancer to extend patient survival...